Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;112(6):957-963.
doi: 10.1111/ejh.14191. Epub 2024 Feb 18.

Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR

Jan-Michel Heger  1   2   3 , Yannick d'Hargues  1   2   4 , Fanni Kleinert  1 , Julia Mattlener  1   2 , Jonathan Weiss  1   2 , Fabian Franzen  1   2 , Christian Becker  5 , Kerstin Becker  5 , Philipp Gödel  1   2   3 , Marcel Schmiel  6 , Jörn Meinel  6 , Ruth Flümann  1   2   3 , Florian Simon  1   2 , H Christian Reinhardt  2   7 , Peter Borchmann  1   2   3 , Sven Borchmann  1   2   3 , Hyatt Balke-Want  1   2   3   8 , Gero Knittel  2   4   7 , Bastian von Tresckow  1   7
Affiliations

Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR

Jan-Michel Heger et al. Eur J Haematol. 2024 Jun.

Abstract

Although several promising approaches for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) have been approved recently, it remains unclear which patients will ultimately achieve long-term responses. Circulating tumor (ct)DNA sequencing has emerged as a valuable tool to assess minimal residual disease (MRD). Correlations between MRD and outcomes have been shown in previously untreated DLBCL, but data on the repeated assessment of MRD in the dynamic course of rrDLBCL is limited. Here, we present an approach leveraging cost- and time-sensitivity of digital droplet (dd)PCR to repeatedly assess MRD in rrDLBCL and present proof-of-principle for its ability to predict outcomes.

Keywords: LBCL; MRD; ctDNA; ddPCR; liquid biopsy.

PubMed Disclaimer

References

REFERENCES

    1. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B‐cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184‐4190.
    1. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B‐cell lymphoma. New Engl J Med. 2019;380(1):45‐56.
    1. Salles G, Duell J, Barca EG, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B‐cell lymphoma (L‐MIND): a multicentre, prospective, single‐arm, phase 2 study. Lancet Oncol. 2020;21(7):978‐988.
    1. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B‐cell lymphoma. J Clin Oncol. 2020;38(2):155‐165.
    1. Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: observations from the JULIET, ZUMA‐1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295‐1312.

LinkOut - more resources